Get the Stockscreener App
40.45
6.20%
2.36
After Hours:
40.90
0.45
+1.11%
Arrowhead Pharmaceuticals Inc stock is traded at $40.45, with a volume of 3.51M.
It is up +6.20% in the last 24 hours and up +6.36% over the past month.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
See More
Previous Close:
$38.09
Open:
$38.01
24h Volume:
3.51M
Relative Volume:
1.56
Market Cap:
$5.59B
Revenue:
$181.74M
Net Income/Loss:
$-143.97M
P/E Ratio:
-29.10
EPS:
-1.39
Net Cash Flow:
$9.60M
1W Performance:
-1.96%
1M Performance:
+6.36%
6M Performance:
+164.21%
1Y Performance:
+121.28%
1-Day Range:
$37.43
$40.58
1-Week Range:
$37.06
$43.59
52-Week Range:
$9.57
$43.69
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
40.45 | 5.27B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-24 | Initiated | Goldman | Neutral |
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
Goldman Sachs Reaffirms Their Hold Rating on Arrowhead Pharmaceuticals (ARWR) - The Globe and Mail
Analyzing Arrowhead Pharmaceuticals After Doubling in Price With RNA Therapy Breakthroughs - Yahoo Finance
A Look at Arrowhead Pharmaceuticals’s Valuation Following FDA Approval of First siRNA Therapy for Rare Disease - Yahoo Finance
How Analyst Views Are Shifting as Arrowhead Pharmaceuticals Enters a New Phase of Growth - Yahoo Finance
Arrowhead rises as FDA approves lead drug for rare disorder - MSN
Arrowhead Pharma (ARWR): Analyst Rating Update on November 20, 2 - GuruFocus
How supply chain issues affect Arrowhead Pharmaceuticals Inc. stockSwing Trade & Trade Opportunity Analysis - newser.com
Is Arrowhead Pharmaceuticals Inc. (HDP1) stock supported by free cash flow2025 Institutional Moves & Consistent Growth Stock Picks - newser.com
Arrowhead Pharma stock price target raised to $70 from $45 at Piper Sandler - Investing.com Canada
What macro factors could drive Arrowhead Pharmaceuticals Inc. (HDP1) stock higherDay Trade & AI Enhanced Execution Alerts - newser.com
Arrowhead Pharma stock gets Buy rating reaffirmed by H.C. Wainwright - Investing.com Canada
RBC Capital Maintains Arrowhead Pharmaceuticals (ARWR) Outperform Recommendation - Nasdaq
Arrowhead’s Redemplo Approval Sets Up Standoff With Ionis’s Tryngolza - Citeline News & Insights
How Arrowhead Pharmaceuticals Inc. (HDP1) stock reacts to Fed tighteningIPO Watch & Long-Term Capital Growth Strategies - newser.com
Will Arrowhead Pharmaceuticals Inc. stock continue dividend increases2025 Year in Review & Momentum Based Trading Ideas - newser.com
ARWR: REDEMPLO Approved by FDA for the Treatment of FCS - Smartkarma
Arrowhead nets first commercial win as siRNA drug garners FDA approval - Yahoo Finance
Can Arrowhead Pharmaceuticals Inc. stock hit analyst price targetsOptions Play & Consistent Profit Focused Trading Strategies - newser.com
Arrowhead Pharmaceuticals Steps Into The Rare Disease Market - Finimize
Arrowhead Pharmaceuticals Poised for Commercial Transition After First FDA Approval, RBC Says - MarketScreener
ARWR: RBC Capital Raises Price Target and Maintains Outperform Rating | ARWR Stock News - GuruFocus
Arrowhead Pharma stock price target raised by RBC to $52 on Redemplo approval - Investing.com Canada
Arrowhead Pharma stock rises as FDA approves Redemplo for FCS treatment - Investing.com Canada
Arrowhead Pharma stock holds steady as Cantor Fitzgerald reiterates Overweight rating - Investing.com Canada
What dividend safety rating applies to Arrowhead Pharmaceuticals Inc. (HDP1) stockMarket Sentiment Report & Weekly Top Performers Watchlists - newser.com
ARWR: Chardan Capital Maintains Buy Rating and $60 Price Target - GuruFocus
Piper Sandler Raises ARWR Price Target to $70.00 | ARWR Stock Ne - GuruFocus
Trend analysis for Arrowhead Pharmaceuticals Inc. this weekWeekly Market Summary & Free Safe Entry Trade Signal Reports - newser.com
Will Arrowhead Pharmaceuticals Inc. stock benefit from upcoming earnings reportsMarket Sentiment Report & Real-Time Volume Analysis - newser.com
FDA nod for Arrowhead’s Redemplo in FCS - The Pharma Letter
Why Arrowhead Pharmaceuticals Inc. (HDP1) stock signals breakout potential - newser.com
How Arrowhead Pharmaceuticals Inc. (HDP1) stock behaves under inflation pressureWeekly Earnings Recap & Low Risk High Reward Ideas - newser.com
Will Arrowhead Pharmaceuticals Inc. stock gain from lower inflationMarket Sentiment Review & Free Technical Pattern Based Buy Signals - newser.com
Arrowhead Is A Buy On REDEMPLO(TM) Approval And Strong Cash Runway - Seeking Alpha
Arrowhead Pharmaceuticals’ REDEMPLO Approved by FDA - MSN
With FDA Approval for RNAi Drug, Arrowhead Pharma Starts Price War With Rival Ionis - MedCity News
Risk vs reward if holding onto Arrowhead Pharmaceuticals Inc.2025 Top Gainers & Fast Moving Stock Trade Plans - newser.com
Arrowhead Pharmaceuticals(ARWR) Stock: Climbs Following FDA Approval of REDEMPLO for Rare Disease Treatment - parameter.io
Arrowhead Secures Maiden Approval, First FDA Nod for Rare Genetic Metabolic Disorder - BioSpace
Arrowhead Just Won FDA Approval, But the Math Tells a Different Story - CTOL Digital Solutions
US FDA approves Arrowhead's genetic disorder drug - Reuters
Arrowhead’s plozasiran cleared for FCS; Ionis patent duel awaits - BioWorld MedTech
RNAi biotech Arrowhead wins first FDA approval - BioPharma Dive
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® - TradingView
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):